Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -88.11
- Piotroski Score 4.00
- Grade Neutral
- Symbol (ARAV)
- Company Aravive, Inc.
- Price $0.04
- Changes Percentage (-13.39%)
- Change -$0.01
- Day Low $0.04
- Day High $0.05
- Year High $2.46
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.25
- High Stock Price Target $0.25
- Low Stock Price Target $0.25
- Potential Upside/Downside N/A
- Consensus Rating Strong Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.76
- Trailing P/E Ratio -0.052763157894737
- Forward P/E Ratio -0.052763157894737
- P/E Growth -0.052763157894737
- Net Income $-80,921,000
Income Statement
Quarterly
Annual
Latest News of ARAV
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
About 1,500 migrants form a new caravan in Mexico. Here's what it means
Around 1,500 migrants formed a new caravan in Mexico, aiming to reach the U.S. border before Trump's inauguration. Caravans provide safety against authorities but face risks from cartels. Migrants see...
By AP NEWS | 2 days ago -
Evans Defeats Caraveo in Colorado, Flipping a Key House Seat for the G.O.P.
In Colorado, Gabe Evans, a right-wing state representative, defeated Yadira Caraveo, the first Latina elected to federal office in the state....
By The New York Times | 1 week ago -
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Reported Earnings, And Analysts Cut Their Target Price
Maravai LifeSciences Holdings, Inc. reported disappointing quarterly results with lower revenues and larger losses than expected. Analysts have adjusted their forecasts for the company, predicting a s...
By Yahoo! Finance | 1 week ago
